Introduction: Febrile neutropenia (FN) represents a life-threatening complication in hematological malignancies. Its etiology is most often due to infections even though FN of other origins, such as tumor-related fever and non-infectious inflammation, should rapidly be ruled out. Initially, C-reactive protein and, more recently, procalcitonin (PCT) have been proposed as useful biomarkers for differential diagnosis. PCT was shown to be a good biomarker of bacterial infections and their clinical outcomes. Definition of standard cut-offs and design of PCT-guided treatment protocols remain however to be defined.Areas covered: In this review, highlights on the current clinical use of PCT and its potential role as a diagnostic tool have been discussed by a panel of physicians from different areas of expertise. We provide current clinical evidence that PCT has been shown to be a reliable biomarker to differentiate fever of bacterial origin from other causes. Moreover, the Authors convened to a round-table to discuss their real-life experience' and offer their recommendations by a Delphi survey.Expert commentary: PCT has an important clinical role in FN. Issues such as the validation of a specific decision algorithm that includes PCT to monitor antibiotic choice and treatment duration will be addressed in prospective studies.
Titolo: | Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients | |
Autori Riconosciuti: | ||
Autori: | Bruno, Benedetto; Busca, Alessandro; Vallero, Stefano; Raviolo, Stefania; Mordini, Nicola; Nassi, Luca; Cignetti, Alessandro; Audisio, Ernesta; Festuccia, Moreno; Corsetti, Alessandra; Depaoli, Lorella; Faraci, Maura; Micalizzi, Concetta; Corcione, Silvia; Berger, Massimo; Saglio, Francesco; Caropreso, Paola; Mengozzi, Giulio; Squadrone, Vincenzo; De Rosa, Francesco Giuseppe; Giaccone, Luisa | |
Data di pubblicazione: | 2017 | |
Abstract: | Introduction: Febrile neutropenia (FN) represents a life-threatening complication in hematological malignancies. Its etiology is most often due to infections even though FN of other origins, such as tumor-related fever and non-infectious inflammation, should rapidly be ruled out. Initially, C-reactive protein and, more recently, procalcitonin (PCT) have been proposed as useful biomarkers for differential diagnosis. PCT was shown to be a good biomarker of bacterial infections and their clinical outcomes. Definition of standard cut-offs and design of PCT-guided treatment protocols remain however to be defined.Areas covered: In this review, highlights on the current clinical use of PCT and its potential role as a diagnostic tool have been discussed by a panel of physicians from different areas of expertise. We provide current clinical evidence that PCT has been shown to be a reliable biomarker to differentiate fever of bacterial origin from other causes. Moreover, the Authors convened to a round-table to discuss their real-life experience' and offer their recommendations by a Delphi survey.Expert commentary: PCT has an important clinical role in FN. Issues such as the validation of a specific decision algorithm that includes PCT to monitor antibiotic choice and treatment duration will be addressed in prospective studies. | |
Volume: | 10 | |
Fascicolo: | 6 | |
Pagina iniziale: | 543 | |
Pagina finale: | 550 | |
Digital Object Identifier (DOI): | 10.1080/17474086.2017.1326813 | |
Parole Chiave: | Febrile neutropenia; hematological disease; hematopoietic stem cell transplantation; infections; procalcitonin; Biomarkers; C-Reactive Protein; Calcitonin; Diagnosis, Differential; Febrile Neutropenia; Humans; Hematology | |
Rivista: | EXPERT REVIEW OF HEMATOLOGY | |
Appare nelle tipologie: | 03A-Articolo su Rivista |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
PCT haematology Expert review Haem 2017 Bruno.pdf | PDF EDITORIALE | Utenti riconosciuti Richiedi una copia |